The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Pompe disease gene therapy
Open accessAbstract
Pompe disease is an autosomal recessive metabolic myopathy caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase and results in cellular lysosomal and cytoplasmic glycogen accumulation. A wide spectrum of disease exists from hypotonia and severe cardiac hypertrophy in the first few months of life due to severe mutations to a milder form with the onset of symptoms in adulthood. In either condition, the involvement of several systems leads to progressive weakness and disability. In early-onset severe cases, the natural history is characteristically cardiorespiratory failure and death in the first year of life. Since the advent of enzyme replacement therapy (ERT), the clinical outcomes have improved. However, it has become apparent that a new natural history is being defined in which some patients have substantial improvement following ERT, while others develop chronic disability reminiscent of the late-onset disease. In order to improve on the current clinical outcomes in Pompe patients with diminished clinical response to ERT, we sought to address the cause and potential for the treatment of disease manifestations which are not amenable to ERT. In this review, we will focus on the preclinical studies that are relevant to the development of a gene therapy strategy for Pompe disease, and have led to the first clinical trial of recombinant adeno-associated virus-mediated gene-based therapy for Pompe disease. We will cover the preliminary laboratory studies and rationale for a clinical trial, which is based on the treatment of the high rate of respiratory failure in the early-onset patients receiving ERT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781
Self-citationProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Self-citationPompe disease diagnosis and management guideline
Kishnani, P. S., Steiner, R. D., Bali, D., Berger, K., Byrne, B. J., Case, L. E., Crowley, J. F., Downs, S., Howell, R. R., Kravitz, R. M., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000218152.87434.f3 · Cited by 632
Self-citationKishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Self-citationCross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From Milk
Van den Hout, J. M. P., Kamphoven, J. H. J., Winkel, L. P. F., Arts, W. F. M., Klerk, J. B. C. D., Loonen, M. C. B., Vulto, A. G., Cromme-Dijkhuis, A., Weisglas-Kuperus, N., Hop, W., et al. (2004) · Pediatrics · doi:10.1542/peds.113.5.e448 · Cited by 355
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Self-citationRaben, N., Nagaraju, K., Lee, E., Kessler, P., Byrne, B., Lee, L., LaMarca, M., King, C., Ward, J., Sauer, B., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19086 · Cited by 299
Self-citationNicolino, M., Byrne, B., Wraith, J. E., Leslie, N., Mandel, H., Freyer, D. R., Arnold, G. L., Pivnick, E. K., Ottinger, C. J., Robinson, P. H., et al. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e31819d0996 · Cited by 293
Self-citationPompe disease in infants and children
Kishnani, P. S., & Howell, R. R. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.01.053 · Cited by 267
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Self-citationAcid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease)
Raben, N., Plotz, P., & Byrne, B. (2002) · Current Molecular Medicine · doi:10.2174/1566524024605789 · Cited by 241
Self-citationEnzyme replacement therapy in the mouse model of Pompe disease
Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., & Plotz, P. H. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.022 · Cited by 217
Jiang, H., Pierce, G. F., Ozelo, M. C., de Paula, E. V., Vargas, J. A., Smith, P., Sommer, J., Luk, A., Manno, C. S., High, K. A., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.004 · Cited by 207
Neural deficits contribute to respiratory insufficiency in Pompe disease
DeRuisseau, L. R., Fuller, D. D., Qiu, K., DeRuisseau, K. C., Donnelly, W. H., Mah, C., Reier, P. J., & Byrne, B. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902534106 · Cited by 194
Self-citationKikuchi, T., Yang, H. W., Pennybacker, M., Ichihara, N., Mizutani, M., Van Hove, J. L., & Chen, Y. T. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1722 · Cited by 167
Lowenstein, P. R., Mandel, R. J., Xiong, W.-D., Kroeger, K. M., & Castro, M. G. (2007) · Current Gene Therapy · doi:10.2174/156652307782151498 · Cited by 167
Pompe disease: Design, methodology, and early findings from the Pompe Registry
Byrne, B. J., Kishnani, P. S., Case, L. E., Merlini, L., Müller‐Felber, W., Prasad, S., & van der Ploeg, A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.02.004 · Cited by 150
Self-citationEfficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type II
Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y.-T., & Koeberl, D. D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.004 · Cited by 145
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease
Bijvoet, A. G. A., van de Kamp, E. H. M., Kroos, M. A., Ding, J. H., Yang, B.-Z., de Visser, P. J., Bakker, C. E., Verbeet, M. P., Oostra, B. A., Reuser, A. J. J., et al. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.53 · Cited by 143
Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L., Raben, N., Plötz, P. H., & Chen, Y. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.8861 · Cited by 139
Fraites, T. J., Schleissing, M. R., Shanely, R. A., Walter, G. A., Cloutier, D. A., Zolotukhin, I., Pauly, D. F., Raben, N., Plötz, P. H., Powers, S. K., et al. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0580 · Cited by 139
Self-citationElimination of Antibodies to Recombinant Enzyme in Pompe's Disease
Mendelsohn, N. J., Messinger, Y. H., Rosenberg, A. S., & Kishnani, P. S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0806809 · Cited by 136
NERVOUS SYSTEM IN POMPEʼS DISEASE
Gambetti, P. L., DiMauro, S., & Baker, L. W. (1971) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-197107000-00008 · Cited by 128
Pompe's disease: An inborn lysosomal disorder with storage of glycogen
Martin, J. J., de Barsy, T., Hoof, F. V., & Palladini, G. (1973) · Acta Neuropathologica · doi:10.1007/bf00687878 · Cited by 128
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P. A., Hoffman, B. E., & Herzog, R. W. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 122
Self-citationSun, B., Zhang, H., Franco, L. M., Brown, T. T., Bird, A., Schneider, A., & Koeberl, D. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.012 · Cited by 113
Pacak, C. A., Sakai, Y., Thattaliyath, B. D., Mah, C. S., & Byrne, B. J. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-13 · Cited by 111
Self-citationRate of disease progression during long-term follow-up of patients with late-onset Pompe disease
van der Beek, N. A. M. E., Hagemans, M. L. C., Reuser, A. J. J., Hop, W. C. J., van der Ploeg, A. T., van Doorn, P. A., & Wokke, J. H. J. (2008) · Neuromuscular Disorders · doi:10.1016/j.nmd.2008.11.007 · Cited by 109
Temporal Neuropathologic and Behavioral Phenotype of 6neo/6neoPompe Disease Mice
Sidman, R. L., Taksir, T. V., Fidler, J. A., Zhao, M. A., Dodge, J. C., Passini, M. A., Raben, N., Thurberg, B. L., Cheng, S. H., & Shihabuddin, L. S. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181815994 · Cited by 98
Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype
van Til, N. P., Stok, M., Aerts‐Kaya, F., de Waard, M. C., Farahbakhshian, E., Visser, T. P., Kroos, M. A., Jacobs, E. H., Willart, M. A. M., van der Wegen, P., et al. (2010) · Blood · doi:10.1182/blood-2009-11-252874 · Cited by 95
Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer
Cooper, M., Nayak, S., Hoffman, B. E., Terhorst, C., Cao, O., & Herzog, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.161 · Cited by 92
Self-citationCao, O., Hoffman, B. E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., & Herzog, R. W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.159 · Cited by 92
Self-citationMah, C. S., Pacak, C. A., Cresawn, K. O., DeRuisseau, L. R., Germain, S. A., Lewis, M. A., Cloutier, D. A., Fuller, D. D., & Byrne, B. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300100 · Cited by 91
Self-citationJoseph, A. M., Munroe, K. J., Housman, M., Garman, R. D., & Richards, S. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03602.x · Cited by 89
CRIM‐negative infantile Pompe disease: 42‐month treatment outcome
Rohrbach, M., Klein, A., Köhli, A., Veraguth, D., Scheer, I., Balmer, C., Lauener, R. P., & Baumgartner, M. R. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9209-0 · Cited by 84
Sun, B., Kulis, M. D., Young, S. P., Hobeika, A. C., Li, S., Bird, A., Zhang, H., Li, Y., Clay, T. M., Burks, W. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.195 · Cited by 84
POMPEʼS DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE* † ‡
Mancall, E. L., Aponte, G. E., & Berry, R. G. (1965) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196501000-00008 · Cited by 83
Mah, C. S., Falk, D. J., Germain, S. A., Kelley, J. S., Lewis, M. A., Cloutier, D. A., DeRuisseau, L. R., Conlon, T. J., Cresawn, K. O., Fraites, T. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.305 · Cited by 78
Self-citationSun, B., Young, S. P., Li, P., Di, C., Brown, T. T., Salva, M. Z., Li, S., Bird, A., Yan, Z., Auten, R. L., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.133 · Cited by 74
Rucker, M., Fraites, T. J., Porvasnik, S., Lewis, M. A., Zolotukhin, I., Cloutier, D. A., & Byrne, B. J. (2004) · Development · doi:10.1242/dev.01169 · Cited by 73
Self-citationMah, C. S., Cresawn, K. O., Fraites, T. J., Pacak, C. A., Lewis, M. A., Zolotukhin, I., & Byrne, B. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302550 · Cited by 73
Self-citationHoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72
Self-citationZiegler, R. J., Bercury, S. D., Fidler, J. A., Zhao, M. A., Foley, J., Taksir, T. V., Ryan, S., Hodges, B. L., Scheule, R. K., Shihabuddin, L. S., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.010 · Cited by 67
Diagnostic challenges for Pompe disease: An under-recognized cause of floppy baby syndrome
Howell, R. R., Byrne, B. J., Darras, B. T., Kishnani, P. S., Nicolino, M. P., & van der Ploeg, A. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000204462.42910.b8 · Cited by 67
Self-citationNAYAK, S., CAO, O., HOFFMAN, B. E., COOPER, M., ZHOU, S., ATKINSON, M. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03548.x · Cited by 66 · cited 3×
“Alternative approaches towards immune tolerance induction can be developed using immune-suppressive drugs, such as rapamycin or B cell-depleting antibodies (57,58).”
Self-citationZhao, B., Yeo, C. C., & Poh, C. L. (2005) · PROTEOMICS · doi:10.1002/pmic.200401081 · Cited by 63
Cresawn, K. O., Fraites, T. J., Wasserfall, C. H., Atkinson, M. A., Lewis, M., Porvasnik, S., Liu, C., Mah, C. S., & Byrne, B. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.68 · Cited by 61
Self-citationIntractable fever and cortical neuronal glycogen storage in glycogenosis type 2
de Martini, C. C., Ciana, G., Benettoni, A., Katouzian, F., Severini, G. M., Bussani, R., & Bembi, B. (2001) · Neurology · doi:10.1212/wnl.57.5.906 · Cited by 59
Glycogen disease resembling mongolism, cretinism, and amytonia congenita
Clement, D. H., & Godman, G. C. (1950) · The Journal of Pediatrics · doi:10.1016/s0022-3476(50)80174-9 · Cited by 57
Teng, Y.-T., Su, W., Hou, J.-W., & Huang, S.-F. (2004) · PubMed · Cited by 57
Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
Self-citationHester, M. E., Foust, K. D., Kaspar, R. W., & Kaspar, B. K. (2009) · Current Gene Therapy · doi:10.2174/156652309789753383 · Cited by 51
Pauly, D. F., Fraites, T. J., Toma, C., Bayes, H. S., Huie, M. L., Hirschhorn, R., Plötz, P. H., Raben, N., Kessler, P., & Byrne, B. J. (2001) · Human Gene Therapy · doi:10.1089/104303401300042447 · Cited by 50
Self-citationGenetic defects in patients with glycogenosis type II (acid maltase deficiency)
Raben, N., Nichols, R. C., Boerkoel, C. F., & Plötz, P. H. (1995) · Muscle & Nerve · doi:10.1002/mus.880181415 · Cited by 50
Hogan, G. R., Gutmann, L., Schmidt, R., & Gilbert, E. F. (1969) · Neurology · doi:10.1212/wnl.19.9.894 · Cited by 48
Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase
Fuller, M., van der Ploeg, A., Reuser, A. J. J., Anson, D. S., & Hopwood, J. J. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.903_a.x · Cited by 46
GLYCOGEN DISEASE OF SKELETAL MUSCLE
Zellweger, H., Dark, A., & Haidar, G. A. A. (1955) · PEDIATRICS · doi:10.1542/peds.15.6.715 · Cited by 41
Generalized Glycogen Storage Disease in Japanese Quail ( Coturnix coturnix japonica)
Matsui, T., Kuroda, S., Mizutani, M., Kiuchi, Y., Suzuki, K., & Ono, T. (1983) · Veterinary Pathology · doi:10.1177/030098588302000307 · Cited by 38
Foley, J. W., Bercury, S. D., Finn, P. F., Cheng, S. H., Scheule, R. K., & Ziegler, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.110 · Cited by 31
A New Method for Recombinant Adeno-associated Virus Vector Delivery to Murine Diaphragm
Mah, C. S., Fraites, T. J., Cresawn, K. O., Zolotukhin, I., Lewis, M. A., & Byrne, B. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.01.006 · Cited by 28
Self-citationSun, B., Li, S., Bird, A., Yi, H., Kemper, A. R., Thurberg, B. L., & Koeberl, D. D. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1511 · Cited by 27
[Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease].
Willemsen, M., Jira, P. E., Gabreëls, F. J. M., van der Ploeg, A. T., & Smeitink, J. A. M. (1998) · PubMed · Cited by 13
(2006) · Genetics in Medicine · doi:10.1097/00125817-200606000-00008 · Cited by 6
Pacak, C. A., Mah, C. S., Cresawn, K. O., Lewis, M. A., Germain, S. A., & Byrne, B. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.040 · Cited by 2
Self-citation(2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.473 · Cited by 1
Research works printed but not linked: 4
- Teng, 2004, Chang Gung medical journal, 27, 379
- Willemsen, 1998, Nederlands tijdschrift voor geneeskunde, 142, 1388
- 1955, Pediatrics, 5, 715
- 2009, 7, 147
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationGenetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline
Hershberger, R. E., Givertz, M. M., Ho, C. Y., Judge, D. P., Kantor, P. F., McBride, K. L., Morales, A., Taylor, M. R. G., Vatta, M., & Ware, S. M. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.03.004 · Cited by 446
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
“…properties (Maga et al, 2012; Tiels et al, 2012; Zhu et al, 2009), pharmacological chaperones that assist the folding of the mutant enzyme (Okumiya et al, 2007; Parenti et al, 2007) or increase the stability of the recombinant enzyme (Porto et al, 2009, 2012), and gene therapy (Byrne et al, 2011).”
Pompe Disease: From Basic Science to Therapy
Kohler, L., Puertollano, R., & Raben, N. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0655-y · Cited by 234
Metadata
- Authors
- Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., Cloutier, D. A., Porvasnik, S. L., Islam, S., Elmallah, M. K., Martin, A., Smith, B. K., Fuller, D. D., Lawson, L. A., & Mah, C. S.
- Affiliations
- University of Florida Health (US)
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-15
- Volume
- 20
- Issue
- R1
- Pages
- R61-R68
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3095055
- OpenAlex
- W2150843111
- Cited by
- 91
- References
- 69
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 10 · 2018: 7 · 2017: 4 · 2016: 7 · 2015: 14 · 2014: 8 · 2013: 12 · 2012: 11
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Molecular Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL059412, F32HL095282, P01 HL59412-06)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, P01 DK58327-03)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD052682)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Pompe disease, gene therapy, acid alpha-glucosidase deficiency, recombinant adeno-associated virus, enzyme replacement therapy, respiratory failure, glycogen accumulation, lysosomal storage disease, preclinical research, clinical trials
- MeSH terms
- Dependovirus, Clinical Trials as Topic, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Humans, Genetic Therapy, Treatment Outcome, Enzyme Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.